Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vancomycin hydrochloride Clear all

Conditions: Intracameral Antibiotics, Cataract Surgery, Phacoemulsification, Endophthalmitis, Vancomycin, Moxifloxacin
Interventions: Vancomycin, Moxifloxacin, Placebo; Drug
Lead sponsor: Panhandle Eye Group, LLP; Other
Eligibility: 30 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Amarillo, Texas

Conditions: Bone Infection, Osteomyelitis, Septic Arthritis, Joint Infection, Prosthetic Joint Infection
Interventions: Dalbavancin, Vancomycin; Drug
Lead sponsor: Infectious Diseases Physicians, Inc.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Annandale, Virginia

Conditions: Staphylococcal Bacteraemia
Interventions: Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more

Conditions: Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis, Clostridium Difficile Diarrhea, Antibiotic-associated Colitis, Antibiotic-associated Diarrhea
Interventions: GT160-246; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 58
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: MRSA Infections
Interventions: Not listed
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 90 Years
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Ulcerative Colitis, FMT, Fecal Microbiota Transplant
Interventions: Metronidazole, Placebo, Vancomycin, Fecal Microbiota Transplantation; Drug · Biological
Lead sponsor: Ari M Grinspan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Infection, Bacterial Resistance, Respiratory Failure
Interventions: vancomycin or gentamicin, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Clostridium Difficile, Spinal Cord Injury
Interventions: Fidaxomicin 200 mg, Placebo, Vancomycin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sepsis, Critical Illness, Infections, Drug Toxicity
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 17 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infection, Hand Injury Wrist, Hand Injuries, Hand Injuries and Disorders, Hand Arthritis
Interventions: Systemic IV Vancomycin, Bier Block, Vancomycin; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Lumbar Fusion Surgery
Interventions: Intraosseous Vancomycin, Intravenous Vancomycin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infection, Surgery, Nervous System Diseases
Interventions: Vancomycin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 1,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Wounds, Acute Wounds
Interventions: AnaSept®, NSS; Device · Other
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions: Vancomycin (POC), Fidaxomicin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Rhinosinusitis (Diagnosis)
Interventions: Mupirocin, Tobramycin, Levofloxacin, Vancomycin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Clostridium Difficile Infection
Interventions: Oral Vancomycin; Drug
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Liver Diseases
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Interventions: Ceftaroline fosamil; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • Sacramento, California • San Francisco, California + 23 more

Conditions: Streptococcal Sepsis, Hematologic Malignancies
Interventions: Empirical Vancomycin, Prophylactic Vancomycin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Clostridioides Difficile Infection
Interventions: Ursodiol 500 MG; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Colitis
Interventions: Vancomycin, Saline; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Cirrhosis, Hepatic Encephalopathy
Interventions: Placebo, VE303, oral vancomycin; Drug
Lead sponsor: Patricia Bloom; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Clostridium Difficile
Interventions: Fecal Microbiota Transplantation, Sham Fecal Microbiota Transplantation; Biological
Lead sponsor: Colleen Kelly; Other
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: The Bronx, New York • Providence, Rhode Island

Search by objective public record fields.

Intracameral Antibiotic Safety Study

Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea

Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis

Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury

Optimizing Vancomycin Therapy in Children

Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration

IO Vancomycin Spine

Topical Vancomycin for Neurosurgery Wound Prophylaxis

Randomized Double-Blind Controlled Clinical Trial

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

Topical Antibiotics in Chronic Rhinosinusitis

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

Vancomycin Resistant Enterococci in Patients Awaiting Liver Transplantation at the University of Michigan: Prevalence, Risk Factors, Natural History and Outcome of Colonization

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

VE303 for Treatment of Hepatic Encephalopathy (HE)

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Fecal Transplant for Relapsing C. Difficile Infection